Sec Form 4 Filing - Lopez Fabio @ SELLAS Life Sciences Group, Inc. - 2018-09-24

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Lopez Fabio 2. Issuer Name and Ticker or Trading Symbol SELLAS Life Sciences Group, Inc. [ SLS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner _____ Officer (give title below) X __ Other (specify below) Former Director, 10% holder (Last) (First) (Middle) EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD 3. Date of Earliest Transaction (MM/DD/YY) 09/24/2018 (Street) HAMILTON, D0HM08 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 09/24/2018 J( 1 ) 1,521,863 D $ 0 0 ( 2 ) D Common Stock 09/24/2018 J( 3 ) 676,324 D $ 0 0 ( 4 ) D Common Stock 09/24/2018 J( 5 ) 325,799 D $ 0 0 ( 6 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Lopez Fabio EQUILIBRIA CAPITAL MANAGEMENT LTD. ONE BERMUDIANA ROAD HAMILTON, D0HM08 Former Director, 10% holder EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. HAMILTON, D0HM08 X EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. HAMILTON, D0HM08 X EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund` C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. ONE BERMUDIANA ROAD HAMILTON, D0HM08 X Equilibria Capital Management Ltd C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. ONE BERMUDIANA ROAD HAMILTON, D0HM08 X Castilian Ltd. C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. ONE BERMUDIANA ROAD HAMILTON, D0HM08 X Varibobi Financial Holdings Ltd C/O EQUILIABRIA CAPITAL MANAGEMENT LTD. O'HARA HOUSE, ONE BERMUDIANA ROAD HAMILTON, D0HM08 X Tafur Daniel C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. ONE BERMUDIANA ROAD HAMILTON, D0HM08 X EQC Private Markets II SAC Fund Ltd-EQC Biotech Sely III Fund C/O EQUILIBRIA CAPITAL MANAGEMENT LTD. ONE BERMUDIANA ROAD HAMILTONHM08 X Signatures Fabio Lopez, by /s/ Ron A. Metzger, Attorney-in-Fact 09/25/2018 Signature of Reporting Person Date EQC Private Markets SAC Fund II Ltd EQC Biotech Sely S Fund, Daniel Tafur, Director, by /s/ Ron A. Metzger, Attorney-in-Fact 09/25/2018 Signature of Reporting Person Date EQC Private Markets SAC Fund Ltd EQC Biotech Sely I Fund, Daniel Tafur, Director, by /s/ Ron A. Metzger, Attorney-in-Fact 09/25/2018 Signature of Reporting Person Date EQC Private Markets SAC Fund Ltd EQC Biotech Sely II Fund, Daniel Tafur, by /s/ Ron A. Metzger, Attorney-in-Fact 09/25/2018 Signature of Reporting Person Date EQC Private Markets II SAC Fund Ltd EQC Biotech Sely III Fund, Daniel Tafur, by /s/ Ron A. Metzger, Attorney-in-Fact 09/25/2018 Signature of Reporting Person Date Equilibria Capital Management Limited, Daniel Tafur, by /s/ Ron A. Metzger, Attorney-in-Fact 09/25/2018 Signature of Reporting Person Date Castilian, Ltd., Daniel Tafur, by /s/ Ron A. Metzger, Attorney-in-Fact 09/25/2018 Signature of Reporting Person Date Varibobi Financial Holdings Ltd., Fabio Lopez, by /s/ Ron A. Metzger, Attorney-in-Fact 09/25/2018 Signature of Reporting Person Date Daniel Tafur, by /s/ Ron A. Metzger, Attorney-in-Fact 09/25/2018 Signature of Reporting Person Date

Explanation of Responses:

( 1 )EQC Private Markets SAC Fund II Ltd-EQC Biotech Sely S Fund ("Sely S") distributed 1,521,863 shares to its partners on a pro rata basis, for no consideration. ( 2 )As a partner of Sely S, Fabio Lopez, received 19,524 of the shares distributed by Sely S. ( 3 )EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund ("Sely I") distributed 676,324 shares to its partners on a pro rata basis, for no consideration. ( 4 )As partners of Sely I, Daniel Tafur and Equilibria Capital Management received 13,871 and 107,619, respectively, of the shares distributed by Sely I. ( 5 )EQC Private Markets SAC Fund Ltd-EQC Biotech Sely II Fund ("Sely II") distributed 325,799 shares to its partners on a pro rata basis, for no consideration. ( 6 )As partners of Sely II, Fabio Lopez and Daniel Tafur received 6,325 and 2,372, respectively, of the shares distributed by Sely II.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.